Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure
Authors:
- 13 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (2) , 508-519
Abstract
Aims: Management of acute decompensated heart failure (ADHF) requires disparate treatments depending on the state of systemic/peripheral perfusion and the presence/absence of expanded body–fluid volumes. There is an unmet need for therapeutics that differentially treat each aspect. Atrial natriuretic peptide (ANP) plays an important role in blood pressure and volume regulation. We investigate for the first time the integrated haemodynamic, endocrine and renal effects of human ANP analogues, modified for exclusive vasodilatory (ANP-DRD) or diuretic (ANP-DGD) activities, in normal health and experimental ADHF. Methods and results: We compared the effects of incremental infusions of ANP analogues ANP-DRD and ANP-DGD with native ANP, in normal (n = 8) and ADHF (n = 8) sheep. ANP-DRD administration increased plasma cyclic guanosine monophosphate (cGMP) in association with dose-dependent reductions in arterial pressure in normal and heart failure (HF) sheep similarly to ANP responses. In contrast to ANP, which in HF produced a diuresis/natriuresis, this analogue was without significant renal effect. Conversely, ANP-DGD induced marked stepwise increases in urinary cGMP, urine volume, and sodium excretion in HF comparable to ANP, but without accompanying vasodilatory effects. All peptides increased packed cell volume relative to control in both states, and in HF, decreased left atrial pressure. In response to ANP-DRD-induced blood pressure reductions, plasma renin activity rose compared to control only during the high dose in normals, and not at all in HF—suggesting relative renin inhibition, with no increase in aldosterone in either state, whereas renin and aldosterone were both significantly reduced by ANP-DGD in HF. Conclusion: These ANP analogues exhibit distinct vasodilatory (ANP-DRD) and diuretic/natriuretic (ANP-DGD) activities, and therefore have the potential to provide precision therapy for ADHF patients with differing pathophysiological derangement of pressure–volume homeostasis.Keywords
Funding Information
- National Health Innovation Centre of Singapore (I2D-1612150)
- Singapore-MIT Alliance for Research and Technology Centre (ING-000101 BIO)
This publication has 33 references indexed in Scilit:
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing ActionsJACC, 2009
- Benefit-Risk Assessment of Nesiritide in the Treatment of Acute Decompensated Heart FailureDrug Safety, 2007
- Acute decompensated heart failure: the cardiorenal syndrome.Cleveland Clinic Journal of Medicine, 2006
- Cardiac natriuretic peptides for cardiac healthClinical Science, 2004
- Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen UptakeCirculation, 2003
- Influence of ANP on Sympathetic Nerve Activity and Chronotropic Regulation of the HeartJournal of Cardiovascular Electrophysiology, 1993
- Atrial Natriuretic Peptide Inhibits a Cation Channel in Renal Inner Medullary Collecting Duct CellsScience, 1989
- Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidneyNature, 1986
- Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factorNature, 1984